Total Payments
$79,009
2024 Payments
$12,635
Companies
30
Transactions
146
Medicare Patients
3,722
Medicare Billing
$552,493
Payment Breakdown by Category
Consulting$50,239 (63.6%)
Other$15,917 (20.1%)
Food & Beverage$5,204 (6.6%)
Research$4,600 (5.8%)
Travel$3,048 (3.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,239 | 24 | 63.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,917 | 6 | 20.1% |
| Food and Beverage | $5,204 | 96 | 6.6% |
| Unspecified | $4,600 | 2 | 5.8% |
| Travel and Lodging | $3,048 | 18 | 3.9% |
Payments by Type
General
$74,409
144 transactions
Research
$4,600
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $25,180 | 17 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $23,183 | 26 | $0 (2023) |
| Merck Sharp & Dohme LLC | $11,758 | 15 | $0 (2024) |
| PFIZER INC. | $4,687 | 6 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $2,887 | 14 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $2,675 | 4 | $0 (2018) |
| GENZYME CORPORATION | $2,606 | 3 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,880 | 1 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $935.00 | 1 | $0 (2024) |
| Medtronic, Inc. | $447.34 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,635 | 24 | Janssen Research & Development, LLC ($9,800) |
| 2023 | $18,975 | 27 | Merck Sharp & Dohme LLC ($7,750) |
| 2022 | $7,302 | 10 | Janssen Research & Development, LLC ($5,200) |
| 2021 | $5,361 | 12 | Janssen Research & Development, LLC ($2,800) |
| 2020 | $13,335 | 9 | Bayer HealthCare Pharmaceuticals Inc. ($7,140) |
| 2019 | $294.05 | 6 | Dendreon Pharmaceuticals LLC ($229.72) |
| 2018 | $11,692 | 34 | Bayer HealthCare Pharmaceuticals Inc. ($10,044) |
| 2017 | $9,415 | 24 | Bayer HealthCare Pharmaceuticals Inc. ($5,850) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 12/17/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Consulting Fee | Cash or cash equivalent | $935.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 11/01/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Boston Scientific Corporation | AMS 700 (Device) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: AMS 700_URO | ||||||
| 10/18/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 10/08/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Oncology | ||||||
| 09/04/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 05/22/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Oncology | ||||||
| 05/17/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2024 | Boston Scientific Corporation | AMS 700 (Device) | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: AMS 700_URO | ||||||
| 05/04/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $125.00 | General |
| Category: UROLOGY | ||||||
| 04/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Oncology | ||||||
| 04/02/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Oncology | ||||||
| 01/10/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Oncology | ||||||
| 01/09/2024 | PFIZER INC. | ELREXFIO (Drug), TRAZIMERA | — | In-kind items and services | $1,400.00 | Research |
| Study: GEDATOLISIB PF06840003 PF04691502 PF06939999 PF06650808 ELRANATAMAB PF06952229 PF06821497 PF07265807 PF06804103 TRASTUZUMAB PFIZER PF06664178 PF06940434 NIROGACESTAT PF06671008 TINLORAFENIB PF06753512 MAVELERTI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/04/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: Oncology | ||||||
| 11/30/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $149.21 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| COFETUZUMAB PELIDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| GEDATOLISIB PF06840003 PF04691502 PF06939999 PF06650808 ELRANATAMAB PF06952229 PF06821497 PF07265807 PF06804103 TRASTUZUMAB PFIZER PF06664178 PF06940434 NIROGACESTAT PF06671008 TINLORAFENIB PF06753512 MAVELERTI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 736 | 1,077 | $508,879 | $88,761 |
| 2022 | 13 | 802 | 1,219 | $560,618 | $97,723 |
| 2021 | 14 | 814 | 1,496 | $525,708 | $123,739 |
| 2020 | 21 | 1,370 | 2,876 | $771,493 | $242,271 |
Total Patients
3,722
Total Services
6,668
Medicare Billing
$552,493
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 191 | 350 | $177,324 | $37,005 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 300 | 429 | $158,374 | $29,502 | 18.6% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 47 | 76 | $53,250 | $5,484 | 10.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $21,168 | $4,241 | 20.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $17,266 | $3,342 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 62 | $14,368 | $3,309 | 23.0% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 18 | 26 | $45,360 | $2,938 | 6.5% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 14 | 14 | $10,115 | $1,383 | 13.7% |
| 55876 | Placement of device in prostate for radiation therapy | Facility | 2023 | 14 | 14 | $7,472 | $694.58 | 9.3% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 17 | 24 | $2,191 | $451.42 | 20.6% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 16 | 17 | $1,991 | $410.18 | 20.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 203 | 387 | $182,411 | $39,690 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 300 | 471 | $164,994 | $31,013 | 18.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 46 | 46 | $29,610 | $6,373 | 21.5% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 48 | 77 | $51,397 | $4,218 | 8.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $20,334 | $3,942 | 19.4% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2022 | 20 | 33 | $50,165 | $3,689 | 7.4% |
| 55700 | Biopsy of prostate gland | Facility | 2022 | 23 | 23 | $17,384 | $2,244 | 12.9% |
| 55874 | Injection of biodegradable material next to prostate | Facility | 2022 | 18 | 18 | $11,016 | $2,139 | 19.4% |
| 55700 | Biopsy of prostate gland | Office | 2022 | 13 | 13 | $11,226 | $1,226 | 10.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 26 | $6,324 | $1,140 | 18.0% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2022 | 25 | 41 | $3,534 | $789.19 | 22.3% |
| 55876 | Placement of device in prostate for radiation therapy | Facility | 2022 | 17 | 17 | $8,564 | $618.23 | 7.2% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2022 | 13 | 13 | $1,508 | $329.11 | 21.8% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2022 | 13 | 13 | $2,151 | $313.40 | 14.6% |
About Dr. Kelly Stratton, MD
Dr. Kelly Stratton, MD is a Urology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1154525640.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kelly Stratton, MD has received a total of $79,009 in payments from pharmaceutical and medical device companies, with $12,635 received in 2024. These payments were reported across 146 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($50,239).
As a Medicare-enrolled provider, Stratton has provided services to 3,722 Medicare beneficiaries, totaling 6,668 services with total Medicare billing of $552,493. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Student in an Organized Health Care Education/Training Program, Urology
- Location Oklahoma City, OK
- Active Since 06/11/2007
- Last Updated 06/23/2017
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1154525640
Products in Payments
- Xofigo (Drug) $18,540
- Nubeqa (Drug) $4,643
- PROVENGE (Drug) $2,979
- JEVTANA (Drug) $2,606
- ZYTIGA (Drug) $2,550
- LYNPARZA (Drug) $1,880
- KEYTRUDA (Biological) $1,623
- ELREXFIO (Drug) $1,400
- ADSTILADRIN (Biological) $935.00
- TECENTRIQ (Biological) $456.54
- Signia (Device) $433.44
- Cysview (Drug) $288.97
- ERLEADA (Drug) $210.04
- Erleada (Drug) $157.43
- Tulsa-Pro (Device) $156.22
- Endocare Cryocare System (Device) $154.34
- XTANDI (Drug) $136.97
- JELMYTO (Drug) $127.75
- GEMTESA (Drug) $125.00
- ELIGARD (Drug) $121.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Oklahoma City
Dr. Mohammad Ramadan, Md, MD
Urology — Payments: $158,035
Urology $158,035
Michael Cookson, Md, MD
Urology — Payments: $142,018
Urology $142,018
Basel Hassoun, Md, MD
Urology — Payments: $124,197
Urology $124,197
Dr. Ashley Bowen, M.d.,M.b.a, M.D.,M.B.A
Urology — Payments: $33,045
Urology $33,045
Sardar Mohammad Khan Galzie, Md, MD
Urology — Payments: $23,330
Urology $23,330
Dominic Frimberger, Md, MD
Urology — Payments: $20,216
Urology $20,216